A citation-based method for searching scientific literature

Michael A Nauck, Daniel R Quast, Jakob Wefers, Andreas F H Pfeiffer. Diabetes Obes Metab 2021
Times Cited: 14







List of co-cited articles
57 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
106
28

Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome.
Nicola Abate, Hanaa S Sallam, Manfredi Rizzo, Dragana Nikolic, Milan Obradovic, Predrag Bjelogrlic, Esma R Isenovic. Curr Pharm Des 2014
60
21

Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management.
Anca Pantea Stoian, Yajnavalka Banerjee, Ali A Rizvi, Manfredi Rizzo. Metab Syndr Relat Disord 2020
51
21

COVID-19 and diabetes management: What should be considered?
Antonio Ceriello, Anca Pantea Stoian, Manfredi Rizzo. Diabetes Res Clin Pract 2020
62
21


Who needs to care about small, dense low-density lipoproteins?
M Rizzo, K Berneis. Int J Clin Pract 2007
66
21

Ethnic differences in serum lipoproteins and their determinants in South African women.
Julia H Goedecke, Kristina Utzschneider, Mirjam V Faulenbach, Manfredi Rizzo, Kaspar Berneis, Giatgen A Spinas, Joel A Dave, Naomi S Levitt, Estelle V Lambert, Tommy Olsson,[...]. Metabolism 2010
61
21

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.
Dragana Nikolic, Rosaria Vincenza Giglio, Ali A Rizvi, Angelo Maria Patti, Giuseppe Montalto, Francesco Maranta, Domenico Cianflone, Anca Pantea Stoian, Manfredi Rizzo. Diabetes Ther 2021
20
21

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P Frias, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez. Lancet 2021
42
21


Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Stefano Del Prato, Steven E Kahn, Imre Pavo, Govinda J Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan G Wynne, Jeffrey S Riesmeyer, Robert J Heine,[...]. Lancet 2021
24
21

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Nikolaos Mentis, Irfan Vardarli, Lars D Köthe, Jens J Holst, Carolyn F Deacon, Michael Theodorakis, Juris J Meier, Michael A Nauck. Diabetes 2011
105
21

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
172
21

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
67
21

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.
Manfredi Rizzo, Giatgen A Spinas, Mustafa Cesur, Zeynep Ozbalkan, Giovam Battista Rini, Kaspar Berneis. Atherosclerosis 2009
58
14

Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease.
Manfredi Rizzo, Vincenzo Pernice, Arian Frasheri, Kaspar Berneis. Atherosclerosis 2008
63
14

Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
K Berneis, M Rizzo, M Hersberger, G B Rini, G Di Fede, I Pepe, G A Spinas, E Carmina. Int J Clin Pract 2009
60
14

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
Manfredi Rizzo, Ali A Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano,[...]. Cardiovasc Diabetol 2016
72
14

Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes.
M Rizzo, K Berneis, A E Altinova, F B Toruner, M Akturk, G Ayvaz, G B Rini, G A Spinas, M Arslan. Diabet Med 2008
60
14

Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study.
Egle Corrado, Manfredi Rizzo, Giuseppe Coppola, Ida Muratori, Michele Carella, Salvatore Novo. Coron Artery Dis 2008
56
14

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Kaspar Berneis, Manfredi Rizzo, Christoph Stettler, Bernard Chappuis, Monica Braun, Peter Diem, Emanuel R Christ. Expert Opin Pharmacother 2008
59
14

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?
Dragana Nikolic, Maciej Banach, Shekoufeh Nikfar, Pooneh Salari, Dimitri P Mikhailidis, Peter P Toth, Mohammad Abdollahi, Kausik K Ray, Michael J Pencina, Jolanta Malyszko,[...]. Int J Cardiol 2013
61
14

Prevalence of dyslipidemia and associated risk factors in Turkish adults.
Fahri Bayram, Derya Kocer, Kursat Gundogan, Ahmet Kaya, Ozgur Demir, Ramazan Coskun, Tevfik Sabuncu, Ahmet Karaman, Mustafa Cesur, Manfredi Rizzo,[...]. J Clin Lipidol 2014
68
14

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S McAdams, Ali A Rizvi, Francesco Cosentino. Biochim Biophys Acta Mol Basis Dis 2018
64
14

COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
Soo Lim, Jae Hyun Bae, Hyuk-Sang Kwon, Michael A Nauck. Nat Rev Endocrinol 2021
277
14

Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Peter P Toth, Marcin Barylski, Dragana Nikolic, Manfredi Rizzo, Giuseppe Montalto, Maciej Banach. Best Pract Res Clin Endocrinol Metab 2014
54
14

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
C Orskov, L Rabenhøj, A Wettergren, H Kofod, J J Holst. Diabetes 1994
729
14

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
372
14


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
14


GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
312
14


The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
154
14


Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
129
14

Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Mikkel B Christensen, Salvatore Calanna, Jens J Holst, Tina Vilsbøll, Filip K Knop. J Clin Endocrinol Metab 2014
58
14

Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
Ryota Usui, Daisuke Yabe, Yutaka Seino. J Diabetes Investig 2019
12
16

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
342
14

How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop. Trends Endocrinol Metab 2020
47
14


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
14

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
265
14

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
483
14


Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016.
Pooyan Kazemian, Fatma M Shebl, Nicole McCann, Rochelle P Walensky, Deborah J Wexler. JAMA Intern Med 2019
90
14


Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
14

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
882
14

Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Zin Z Htike, Francesco Zaccardi, Dimitris Papamargaritis, David R Webb, Kamlesh Khunti, Melanie J Davies. Diabetes Obes Metab 2017
201
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.